We are live on ! Find out more
PDLI

PDL BioPharma, Inc.
PDLI

Delisted

PDLI was delisted on the 30th of December, 2020.

Back to rankings

197 hedge funds and large institutions have $434M invested in PDL BioPharma, Inc. in 2016 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 64 increasing their positions, 60 reducing their positions, and 30 closing their positions.

New
Increased
Maintained
Reduced
Closed

9% more capital invested

Capital invested by funds: $397M → $434M (+$37.1M)

7% more repeat investments, than reductions

Existing positions increased: 64 | Existing positions reduced: 60

2% less call options, than puts

Call options by funds: $2.74M | Put options by funds: $2.8M

2% less funds holding

Funds holding: 201 → 197 (-4)

13% less first-time investments, than exits

New positions opened: 26 | Existing positions closed: 30

Holders
197
Holders Change
-4
Holders Change %
-1.99%
% of All Funds
5.26%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0.05%
New
26
Increased
64
Reduced
60
Closed
30
Calls
$2.74M
Puts
$2.8M
Net Calls
-$53K
Net Calls Change
+$1.45M

Top Buyers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
+$8.35M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$6.72M
3
Renaissance Technologies
Renaissance Technologies
New York
+$2.88M
4
Mackenzie Financial
Mackenzie Financial
Ontario, Canada
+$2.35M
5
GPP
Great Point Partners
Connecticut
+$2.05M

Top Sellers

Rank Fund Capital Flow
1
Bank of New York Mellon
Bank of New York Mellon
New York
-$6.54M
2
GAM
Gotham Asset Management
New York
-$3.26M
3
AAM
Advisors Asset Management
Colorado
-$2.78M
4
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$2.63M
5
EA
Emerald Acquisition
Washington
-$2.62M
Name Holding Trade Value Shares
Change 		Change in
Stake
Connor, Clark & Lunn Investment Management (CC&L)
26
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$4.67M -$69.2K -21,800 -2%
Wellington Management Group
27
Wellington Management Group
Massachusetts
$4.47M +$2.99K +942 +0.1%
Morgan Stanley
28
Morgan Stanley
New York
$4.25M +$1.5M +472,357 +59%
GAM
29
Gotham Asset Management
New York
$4.24M -$3.26M -1,027,402 -45%
NI
30
Numeric Investors
Massachusetts
$3.65M +$146K +46,000 +4%
JIM
31
Jupiter Investment Management
United Kingdom
$3.56M +$1.36M +429,348 +68%
Prudential Financial
32
Prudential Financial
New Jersey
$3.33M +$202K +63,590 +7%
Two Sigma Advisers
33
Two Sigma Advisers
New York
$3.23M -$291K -91,800 -9%
Deutsche Bank
34
Deutsche Bank
Germany
$3.17M +$1.66M +524,161 +124%
Two Sigma Investments
35
Two Sigma Investments
New York
$3.16M -$570K -179,691 -16%
Federated Hermes
36
Federated Hermes
Pennsylvania
$3.09M -$163K -51,475 -5%
QI
37
QS Investors
New York
$2.74M -$1.28M -403,715 -33%
Fidelity Investments
38
Fidelity Investments
Massachusetts
$2.74M +$17K +5,350 +0.7%
BIM
39
BlackRock Investment Management
Delaware
$2.29M -$9.15K -2,882 -0.4%
GPP
40
Great Point Partners
Connecticut
$2.16M +$2.05M +645,000 New
California Public Employees Retirement System
41
California Public Employees Retirement System
California
$2.03M +$229K +72,100 +13%
D.E. Shaw & Co
42
D.E. Shaw & Co
New York
$2.03M -$164K -51,804 -8%
ACM
43
Americafirst Capital Management
California
$1.85M +$1.75M +551,804 New
SFM
44
Systematic Financial Management
New Jersey
$1.8M -$174K -54,770 -9%
CCMH
45
Cornerstone Capital Management Holdings
New York
$1.67M +$67.3K +21,200 +4%
AAM
46
Advisors Asset Management
Colorado
$1.61M -$2.78M -874,299 -65%
BCM
47
Bridgeway Capital Management
Texas
$1.6M – – –
HCM
48
Highbridge Capital Management
New York
$1.59M +$1.51M +474,610 New
Allianz Asset Management
49
Allianz Asset Management
Germany
$1.58M +$350K +110,369 +30%
Asset Management One
50
Asset Management One
Japan
$1.44M – – –
1
2
3 4 5

PDLI Hedge Fund Activity: Q3 2016 in Review

197 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in PDL BioPharma, Inc. (PDLI) for Q3 2016, worth a combined $434M — up 9.4% from $397M a quarter earlier.

Sellers outnumbered buyers: 30 funds closed out of PDLI and 26 opened new positions — a net loss of 4 holders — while 60 trimmed existing stakes and 64 added.

The largest buyer was Armistice Capital, opening a new position worth an estimated $8.35M. The largest seller was Bank of New York Mellon, cutting an estimated $6.54M.

  • 197 institutional investors held PDL BioPharma, Inc. (PDLI) as of Q3 2016, down from 201 in Q2 2016.
  • Funds reported $434M of PDL BioPharma, Inc. stock for Q3 2016, up 9.4% quarter-over-quarter.
  • 26 funds opened new PDL BioPharma, Inc. positions in Q3 2016 and 30 closed out, a net change of -4 holders.
  • The largest PDL BioPharma, Inc. buyer in Q3 2016 was Armistice Capital, an estimated $8.35M added.
  • The largest PDL BioPharma, Inc. seller in Q3 2016 was Bank of New York Mellon, an estimated $6.54M sold.

Based on aggregated 13F filings for Q3 2016.